Board of Directors

Philippe Chambon, M.D., Ph.D.

Phillippe Chambon, is a Managing Director and founder of New Leaf Venture Partners, LLC (NLV Partners). NLV Partners recently came about with the spin-off of the healthcare team from The Sprout Group. Prior to NLV, Philippe was a General Partner at Sprout, which he joined in 1995. He has been a founding investor in five companies and led multiple later stage investments and one buy-out. He is an active investor in all three sectors of interest for NLV. In addition to serving on VaxInnate’s board of directors, Philippe serves on the boards of directors of Karos Pharmaceuticals, QPID Health, Treato and Truveris. His prior investments include Auxilium Pharmaceuticals, ePocrates, NxStage Medical, Cephalon, Focus Technologies, Sapient Health Network (WebMD), Charles River Laboratories and Combichem. Immediately prior to joining Sprout, Philippe was a Manager in the healthcare practice of the Boston Consulting Group. Previously, Philippe was an executive with Sandoz Pharmaceutical for seven years, where he built and led an organization responsible for late stage clinical project management, portfolio management, and pre-marketing activities. He conducted graduate research in molecular immunology at The Pasteur Institute. He earned an M.D. and Ph.D. from the University of Paris, and an MBA from Columbia University.


 

Augustine Lawlor

Augustine (Gus) Lawlor is the Managing Partner of HealthCare Ventures, LLC. He has over twenty years operating experience in the healthcare biotechnology industry in finance, business development, mergers and acquisitions and general management. Before joining HealthCare Ventures, Gus was Chief Operating Officer of LeukoSite, Inc. Prior to LeukoSite, he was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technology. He was previously Chief Financial Officer and Vice President of Business Development of BioSurface Technology. Gus serves on the Boards of Directors of Catalyst Biosciences, in S. San Francisco, CA; Dynogen Pharmaceuticals, in Boston, MA; FoldRx Pharmaceuticals, Inc., in Cambridge, MA; GlobeImmune, Inc., in Aurora, CO; Human Genome Sciences, Inc., in Rockville, MD; Promedior, Inc., in Malvern, PA; Replidyne, Inc., in Louisville, CO; Synovex Corporation, in Cambridge, MA; U.S. Genomics, in Woburn, MA; and the Slater Center in Providence, RI. He received a Master’s Degree in Management from Yale University.


 

Wayne F. Pisano

Wayne Pisano joined VaxInnate as interim Chief Executive Officer in January 2012 and as permanent CEO in April 2012. Wayne is the former President and CEO of Sanofi Pasteur, the largest company entirely dedicated to vaccines. Wayne joined Sanofi Pasteur as Vice President, U.S. Marketing in 1997 and held positions of increasing responsibility, including Head of Global Commercial Operations and Corporate Strategy. Wayne is credited with Sanofi Pasteur’s leading worldwide role in the influenza vaccine market with approximately 50 percent of global sales. Following Wayne’s entry into the company, Sanofi Pasteur strengthened its position as the world leader in the vaccine industry, offering a broad range of vaccines that protect against 20 infectious diseases. Along with leading the development and implementation of Sanofi Pasteur’s commercial strategy, Wayne focused Sanofi Pasteur’s R&D strategy and pipeline on identifying and furthering vaccines to protect against diseases that impact both developed and developing nations equally. Wayne holds a bachelor’s degree in biology from St. John Fisher College, Rochester, New York, and an MBA from the University of Dayton, Ohio.